1a1p

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1a1p.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1a1p.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1a1p| PDB=1a1p | SCENE= }}
{{STRUCTURE_1a1p| PDB=1a1p | SCENE= }}
-
'''COMPSTATIN, NMR, 21 STRUCTURES'''
+
===COMPSTATIN, NMR, 21 STRUCTURES===
-
==Overview==
+
<!--
-
The third component of complement, C3, plays a central role in activation of the classical, alternative, and lectin pathways of complement activation. Recently, we have identified a 13-residue cyclic peptide (named Compstatin) that specifically binds to C3 and inhibits complement activation. To investigate the topology and the contribution of each critical residue to the binding of Compstatin to C3, we have now determined the solution structure using 2D NMR techniques; we have also synthesized substitution analogues and used these to study the structure-function relationships involved. Finally, we have generated an ensemble of a family of solution structures of the peptide with a hybrid distance geometry-restrained simulated-annealing methodology, using distance, dihedral angle, and 3J(NH-Halpha)-coupling constant restraints. The Compstatin structure contained a type I beta-turn comprising the segment Gln5-Asp6-Trp7-Gly8. Preference for packing of the hydrophobic side chains of Val3, Val4, and Trp7 was observed. The generated structure was also analyzed for consistency using NMR parameters such as NOE connectivity patterns, 3J(NH-Halpha)-coupling constants, and chemical shifts. Analysis of Ala substitution analogues suggested that Val3, Gln5, Asp6, Trp7, and Gly8 contribute significantly to the inhibitory activity of the peptide. Substitution of Gly8 caused a 100-fold decrease in inhibitory potency. In contrast, substitution of Val4, His9, His10, and Arg11 resulted in minimal change in the activity. These findings indicate that specific side-chain interactions and the beta-turn are critical for preservation of the conformational stability of Compstatin and they might be significant for maintaining the functional activity of Compstatin.
+
The line below this paragraph, {{ABSTRACT_PUBMED_9541394}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 9541394 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_9541394}}
==About this Structure==
==About this Structure==
-
Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1A1P OCA].
+
Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1A1P OCA].
==Reference==
==Reference==
Line 29: Line 33:
[[Category: Nmr]]
[[Category: Nmr]]
[[Category: Peptide structure]]
[[Category: Peptide structure]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 09:40:25 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jun 30 15:48:00 2008''

Revision as of 12:48, 30 June 2008

Image:1a1p.png

Template:STRUCTURE 1a1p

COMPSTATIN, NMR, 21 STRUCTURES

Template:ABSTRACT PUBMED 9541394

About this Structure

Full experimental information is available from OCA.

Reference

Solution structure of Compstatin, a potent complement inhibitor., Morikis D, Assa-Munt N, Sahu A, Lambris JD, Protein Sci. 1998 Mar;7(3):619-27. PMID:9541394

Page seeded by OCA on Mon Jun 30 15:48:00 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1a1p"
Personal tools